Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Rises By 210.4%

Posted by George Bondi on Jul 28th, 2026

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 9,938 shares, a growth of 210.4% from the June 30th total of 3,202 shares. Based on an average daily volume of 6,876 shares, the short-interest ratio is currently 1.4 days. Approximately 0.0% of the shares of the stock are short sold.

Institutional Trading of Pharming Group

Large investors have recently modified their holdings of the business. SmartHarvest Portfolios LLC purchased a new position in Pharming Group during the fourth quarter valued at $224,000. NewEdge Advisors LLC raised its stake in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Pharming Group in the fourth quarter worth $360,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group during the second quarter valued at $32,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Trading Down 1.2%

Shares of NASDAQ:PHAR traded down $0.15 during midday trading on Tuesday, reaching $12.86. The company’s stock had a trading volume of 4,237 shares, compared to its average volume of 18,336. The firm has a market capitalization of $910.21 million, a price-to-earnings ratio of 80.38 and a beta of -0.04. The firm has a 50 day moving average price of $13.13 and a two-hundred day moving average price of $15.36. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.06 and a current ratio of 2.63. Pharming Group has a fifty-two week low of $9.54 and a fifty-two week high of $21.34.

Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.The company had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million. As a group, analysts forecast that Pharming Group will post 0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Wall Street Zen lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group started coverage on shares of Pharming Group in a report on Friday, April 10th. They set a “buy” rating and a $37.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pharming Group presently has an average rating of “Hold” and an average price target of $38.33.

Get Our Latest Research Report on PHAR

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.